Shah, Nirav N.; Wang, Michael; Roeker, Lindsey E.; Patel, Krish; Woyach, Jennifer A.; Wierda, William G.; Ujjani, Chaitra S.; Eyre, Toby A.; Zinzani, Pier Luigi; Alencar, Alvaro J.; Ghia, Paolo; Lamanna, Nicole; Hoffmann, Marc S.; Patel, Manish R.; Flinn, Ian; Gerson, James N.; Ma, Shuo; Coombs, Catherine C.; Cheah, Chan Y.; Lech-Maranda, Ewa; Fakhri, Bita; Kim, Won Seog; Barve, Minal A.; Cohen, Jonathon B.; Jurczak, Wojciech; Munir, Talha; Thompson, Meghan C.; Tsai, Donald E.; Bao, Katherine; Cangemi, Nicholas A.; Kherani, Jennifer F.; Walgren, Richard A.; Han, Hongmei; Ruppert, Amy S.; Brown, Jennifer R.

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

LANCET HAEMATOLOGY

IF17.7

2024-09-012

PRE

Wierda, William G.; Shah, Nirav N.; Cheah, Chan Y.; Lewis, David; Hoffmann, Marc S.; Coombs, Catherine C.; Lamanna, Nicole; Ma, Shuo; Jagadeesh, Deepa; Munir, Talha; Wang, Yucai; Eyre, Toby A.; Rhodes, Joanna M.; McKinney, Matthew; Lech-Maranda, Ewa; Tam, Constantine S.; Jurczak, Wojciech; Izutsu, Koji; Alencar, Alvaro J.; Patel, Manish R.; Seymour, John F.; Woyach, Jennifer A.; Thompson, Philip A.; Abada, Paolo B.; Ho, Caleb; McNeely, Samuel C.; Marella, Narasimha; Nguyen, Bastien; Wang, Chunxiao; Ruppert, Amy S.; Nair, Binoj; Liu, Hui; Tsai, Donald E.; Roeker, Lindsey E.; Ghia, Paolo

Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models

HAEMATOLOGICA

IF7.9

2024-06-060

OAAI

Characteristics of patients with newly diagnosed hematological malignancies referred for echocardiography

FRONTIERS IN ONCOLOGY

IF3.3

2024-01-243

OAAI

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2023-07-0679

Mato, Anthony R.; Woyach, Jennifer A.; Brown, Jennifer R.; Ghia, Paolo; Patel, Krish; Eyre, Toby A.; Munir, Talha; Lech-Maranda, Ewa; Lamanna, Nicole; Tam, Constantine S.; Shah, Nirav N.; Coombs, Catherine C.; Ujjani, Chaitra S.; Fakhri, Bita; Cheah, Chan Y.; Patel, Manish R.; Alencar, Alvaro J.; Cohen, Jonathon B.; Gerson, James N.; Flinn, Ian W.; Ma, Shuo; Jagadeesh, Deepa; Rhodes, Joanna M.; Hernandez-Ilizaliturri, Francisco; Zinzani, Pier L.; Seymour, John F.; Balbas, Minna; Nair, Binoj; Abada, Paolo; Wang, Chunxiao; Ruppert, Amy S.; Wang, Denise; Tsai, Donald E.; Wierda, William G.; Jurczak, Wojciech

Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group

venetoclax加利妥昔单抗在复发性或难治性慢性淋巴细胞白血病患者中的临床疗效和耐受性-波兰成人白血病研究组的真实世界分析

ANNALS OF HEMATOLOGY

IF2.4

2023-07-016

OAAI

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

HAEMATOLOGICA

IF7.9

2023-06-019

OAAI

Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study